Other news
News
Infinite Looks Announces $4.2M Series A Funding to Champion the Active Textured Hair Community Through its Brand Sunday II Sunday
Read full storyOther news
On Target Laboratories Secures $21 Million for Development and Commercialization of Pafolacianine Sodium Injection
Read full storyOther news
Next-generation Radiopharmaceuticals Company POINT Biopharma to list on NASDAQ through merger with Research Alliance Corp. I
Read full storyOther news
Paige Secures Financing from KKR for Total Series C Funding Round of Over $125 Million
Read full storyOther news
FDA Authorizes Cue Health's COVID-19 Test for At-Home and Over The Counter Use
Read full storyOther news
TechsoMed Raises $7 Million Series B financing led by Axil Capital
Read full storyOther news
ViaCyte and Gore Expand Collaboration to Develop Novel Membrane and Device Technologies that Enhance Delivery of Cell Replacement Therapies for Diabetes
Read full storyPartner news
OrthoSpin Ltd. Raises up to US$5 Million in Series B Financing
Read full storyPartner news
FDA Clearance Brings RefleXion Closer to Expanding Cancer Treatment Market
Read full storyOther news
Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson
Read full storyJNJ Press releases
Big Pharma’s Billion-Dollar Scramble to Invest in Start-ups to Fuel Innovation
Read full storyPartner news
Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis
Read full storyJNJ Press releases
Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides‐type cutaneous T‐cell lymphoma, a rare type of skin cancer
Read full storyIn the media